Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA

The tumour suppressor p53 is a transcription factor that binds DNA in the vicinity of the genes it controls. The affinity of p53 for specific binding sites relative to other DNA sequences is an inherent driving force for specificity, all other things being equal. We measured the binding affinities of systematically mutated consensus p53 DNA-binding sequences using automated fluorescence anisotropy titrations. Based on measurements of the effects of every possible single base-pair substitution of a consensus sequence, we defined the DNA sequence with the highest affinity for full-length p53 and quantified the effects of deviation from it on the strength of protein–DNA interaction. The contributions of individual nucleotides were to a first approximation independent and additive. But, in some cases we observed significant deviations from additivity. Based on affinity data, we constructed a binding predictor that mirrored the existing p53 consensus sequence definition. We used it to search for high-affinity binding sites in the genome and to predict the effects of single-nucleotide polymorphisms in these sites. Although there was some correlation between the Kd and biological function, the spread of the Kds by itself was not sufficient to explain the activation of different pathways by changes in p53 concentration alone.

[1]  R J DUBOS,et al.  Health and disease. , 1960, JAMA.

[2]  T. D. Schneider,et al.  Quantitative analysis of the relationship between nucleotide sequence and functional activity. , 1986, Nucleic acids research.

[3]  P. V. von Hippel,et al.  Selection of DNA binding sites by regulatory proteins. Statistical-mechanical theory and application to operators and promoters. , 1987, Journal of molecular biology.

[4]  T. D. Schneider,et al.  Sequence logos: a new way to display consensus sequences. , 1990, Nucleic acids research.

[5]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[6]  A. Fersht,et al.  Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[8]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.

[9]  Gary D. Stormo,et al.  DNA binding sites: representation and discovery , 2000, Bioinform..

[10]  G. Stormo,et al.  Non-independence of Mnt repressor-operator interaction determined by a new quantitative multiple fluorescence relative affinity (QuMFRA) assay. , 2001, Nucleic acids research.

[11]  Ting Wang,et al.  Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites , 2002, Oncogene.

[12]  N. D. Clarke,et al.  Rationalization of gene regulation by a eukaryotic transcription factor: calculation of regulatory region occupancy from predicted binding affinities. , 2002, Journal of molecular biology.

[13]  G. Stormo,et al.  Additivity in protein-DNA interactions: how good an approximation is it? , 2002, Nucleic acids research.

[14]  S. Cawley,et al.  Unbiased Mapping of Transcription Factor Binding Sites along Human Chromosomes 21 and 22 Points to Widespread Regulation of Noncoding RNAs , 2004, Cell.

[15]  Nicola J. Rinaldi,et al.  Transcriptional regulatory code of a eukaryotic genome , 2004, Nature.

[16]  Jiannis Ragoussis,et al.  Quantitative high-throughput analysis of transcription factor binding specificities. , 2004, Nucleic acids research.

[17]  A. Fersht,et al.  Cooperative binding of tetrameric p53 to DNA. , 2004, Journal of molecular biology.

[18]  A. Fersht,et al.  Crystal Structure of a Superstable Mutant of Human p53 Core Domain , 2004, Journal of Biological Chemistry.

[19]  Gary D. Stormo,et al.  Quantitative analysis of EGR proteins binding to DNA: assessing additivity in both the binding site and the protein , 2005, BMC Bioinformatics.

[20]  P. Hainaut,et al.  25 years of p53 research , 2005 .

[21]  N. D. Clarke,et al.  DIP-chip: rapid and accurate determination of DNA-binding specificity. , 2005, Genome research.

[22]  Michelle R. Campbell,et al.  Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Fersht,et al.  Comparative binding of p53 to its promoter and DNA recognition elements. , 2005, Journal of molecular biology.

[24]  Antonina Andreeva,et al.  Core domain interactions in full-length p53 in solution , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Menendez,et al.  A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Martha L Bulyk,et al.  DNA microarray technologies for measuring protein-DNA interactions. , 2006, Current opinion in biotechnology.

[27]  Christoph Plass,et al.  ChIP-chip comes of age for genome-wide functional analysis. , 2006, Cancer research.

[28]  M. Kitayner,et al.  Structural basis of DNA recognition by p53 tetramers. , 2006, Molecular cell.

[29]  E. Ukkonen,et al.  Genome-wide Prediction of Mammalian Enhancers Based on Analysis of Transcription-Factor Binding Affinity , 2006, Cell.

[30]  Z. Weng,et al.  A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.

[31]  Sebastian Mayer,et al.  Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains* , 2006, Journal of Biological Chemistry.

[32]  D. Lane,et al.  The p53 knowledgebase: an integrated information resource for p53 research , 2007, Oncogene.

[33]  Ruth Nussinov,et al.  Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets , 2007, Nucleic acids research.

[34]  C. Prives,et al.  hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes , 2007, Cell.

[35]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[36]  H. Aburatani,et al.  An integrated map of p53-binding sites and histone modification in the human ENCODE regions. , 2007, Genomics.